IRIS
GANDAGLIA, GIORGIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 10.009
AS - Asia 8.848
NA - Nord America 5.494
SA - Sud America 2.577
AF - Africa 200
OC - Oceania 13
Continente sconosciuto - Info sul continente non disponibili 5
AN - Antartide 1
Totale 27.147
Salva come PNG Salva come JPEG
Nazione #
RU - Federazione Russa 5.204
US - Stati Uniti d'America 5.196
SG - Singapore 3.175
CN - Cina 2.362
BR - Brasile 2.113
IT - Italia 2.082
HK - Hong Kong 1.271
SE - Svezia 1.033
VN - Vietnam 932
FR - Francia 482
BD - Bangladesh 281
DE - Germania 278
AR - Argentina 214
GB - Regno Unito 176
NL - Olanda 175
IN - India 159
FI - Finlandia 152
JP - Giappone 137
CA - Canada 136
TR - Turchia 90
MX - Messico 81
IQ - Iraq 79
IE - Irlanda 71
PL - Polonia 66
ZA - Sudafrica 66
CO - Colombia 65
EC - Ecuador 65
AT - Austria 64
ID - Indonesia 63
ES - Italia 51
MA - Marocco 46
PK - Pakistan 41
SA - Arabia Saudita 35
VE - Venezuela 30
UA - Ucraina 29
PY - Paraguay 27
CL - Cile 23
NP - Nepal 23
UZ - Uzbekistan 23
LT - Lituania 22
PH - Filippine 22
AE - Emirati Arabi Uniti 19
MY - Malesia 18
PE - Perù 18
TN - Tunisia 18
EG - Egitto 17
DO - Repubblica Dominicana 16
KE - Kenya 16
CZ - Repubblica Ceca 14
UY - Uruguay 13
BE - Belgio 12
CR - Costa Rica 12
DZ - Algeria 12
JO - Giordania 12
KR - Corea 12
CH - Svizzera 11
IL - Israele 11
BG - Bulgaria 10
KZ - Kazakistan 10
PT - Portogallo 10
AU - Australia 9
AZ - Azerbaigian 9
HN - Honduras 9
LB - Libano 9
MD - Moldavia 9
JM - Giamaica 8
BA - Bosnia-Erzegovina 7
BO - Bolivia 7
HU - Ungheria 7
IR - Iran 7
NO - Norvegia 7
DK - Danimarca 6
ET - Etiopia 6
GT - Guatemala 6
PA - Panama 6
PR - Porto Rico 6
AL - Albania 5
BH - Bahrain 5
OM - Oman 5
RO - Romania 5
TT - Trinidad e Tobago 5
AM - Armenia 4
BB - Barbados 4
CG - Congo 4
CY - Cipro 4
GR - Grecia 4
SN - Senegal 4
SV - El Salvador 4
SY - Repubblica araba siriana 4
TH - Thailandia 4
BW - Botswana 3
BY - Bielorussia 3
KG - Kirghizistan 3
KH - Cambogia 3
KW - Kuwait 3
MK - Macedonia 3
NI - Nicaragua 3
NZ - Nuova Zelanda 3
PS - Palestinian Territory 3
RS - Serbia 3
Totale 27.110
Salva come PNG Salva come JPEG
Città #
Singapore 1.290
Hong Kong 1.257
Moscow 1.213
Dallas 782
San Jose 723
Ashburn 710
Shanghai 472
Hefei 440
Milan 426
Lawrence 412
Princeton 408
Lauterbourg 385
Ho Chi Minh City 336
New York 254
Beijing 242
Hanoi 207
São Paulo 164
Rome 155
Los Angeles 146
Helsinki 106
Santa Clara 82
Rio de Janeiro 71
Dublin 70
Nuremberg 64
Munich 63
Turin 63
Orem 53
Warsaw 53
Tokyo 50
Boardman 49
Montreal 47
Belo Horizonte 44
Da Nang 43
Brooklyn 42
Florence 41
Chicago 40
Bologna 38
Chennai 37
Verona 37
Brasília 36
Curitiba 34
Guangzhou 34
Haiphong 34
Porto Alegre 34
Buffalo 32
Turku 31
Atlanta 30
Denver 30
Naples 30
Johannesburg 29
Baghdad 28
Manchester 28
Palermo 28
Vienna 28
Biên Hòa 27
Phoenix 27
Toronto 27
Genoa 26
London 26
Stockholm 26
Council Bluffs 25
Houston 25
Salvador 25
Ankara 24
Brescia 24
Frankfurt am Main 24
Mexico City 24
Seattle 24
Amsterdam 23
Bari 23
Buenos Aires 23
The Dalles 23
Guayaquil 22
Manaus 21
San Francisco 21
Columbus 20
Fortaleza 20
Pune 20
Tashkent 20
Thái Bình 20
Boston 19
Campinas 19
Goiânia 19
Poplar 19
Tianjin 19
Erbil 18
Paris 18
Changsha 17
Dhaka 17
Hangzhou 17
Ninh Bình 17
Washington 17
Betim 16
Caxias do Sul 15
Hải Dương 15
Jeddah 15
Kuala Lumpur 15
Mumbai 15
New Delhi 15
Quito 15
Totale 12.528
Salva come PNG Salva come JPEG
Nome #
External Validation of the 2019 Briganti Nomogram for the Identification of Prostate Cancer Patients Who Should Be Considered for an Extended Pelvic Lymph Node Dissection 1.890
Impact of prostate imaging quality (PI-QUAL) score on the detection of clinically significant prostate cancer at biopsy 216
[18F]Fluoro-Deoxy-Glucose positron emission tomography to evaluate lymph node involvement in patients with muscle-invasive bladder cancer receiving neoadjuvant pembrolizumab 210
A NOVEL MODEL INTEGRATING CLINICAL, MP-MRI, AND EPIGENOMIC FEATURES TO PREDICT LYMPH NODE INVASION IN PROSTATE CANCER PATIENTS UNDERGOING RADICAL PROSTATECTOMY AND PELVIC LYMPH NODE DISSECTION 158
[C-11]Choline PET/CT predicts survival in hormone-naive prostate cancer patients with biochemical failure after radical prostatectomy 157
Can Negative Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Avoid the Need for Pelvic Lymph Node Dissection in Newly Diagnosed Prostate Cancer Patients? A Systematic Review and Meta-analysis with Backup Histology as Reference Standard 148
How to optimize follow-up in patients with a suspicious multiparametric MRI and a subsequent negative targeted prostate biopsy. Results from a large, single-institution series 142
68Ga-PSMA-PET/CT Scan as Primary Staging for Prostate Cancer and Its Related Clinical Implications 135
Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer 134
The Role of Prostate-specific Membrane Antigen Positron Emission Tomography for Assessment of Local Recurrence and Distant Metastases in Patients with Biochemical Recurrence of Prostate Cancer After Definitive Treatment: A Systematic Review and Meta-analysis 130
ROBOT-ASSISTED RADICAL PROSTATECTOMY IS ASSOCIATED WITH FASTER AND GREATER RECOVERY FROM ORGASM ASSOCIATED INCONTINENCE 129
A Novel Nomogram to Identify Candidates for Extended Pelvic Lymph Node Dissection Among Patients with Clinically Localized Prostate Cancer Diagnosed with Magnetic Resonance Imaging-targeted and Systematic Biopsies 128
Age and gleason score upgrading between prostate biopsy and radical prostatectomy: Is this still true in the multiparametric resonance imaging era? 127
Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study 126
Impact of Early Dorsal Venous Complex Ligation on Urinary Continence Recovery after Robot-assisted Radical Prostatectomy: Results from a Phase 3 Randomized Controlled Trial 124
Identification of the Optimal Candidates for Nodal Staging with Extended Pelvic Lymph Node Dissection Among Prostate Cancer Patients Who Underwent Preoperative Prostate-specific Membrane Antigen Positron Emission Tomography. External Validation of the Memorial Sloan Kettering Cancer Center and Briganti Nomograms and Development of a Novel Tool 124
[Management of erectile dysfunction in patients with preexisting cardiovascular disease]. FT Disfunzione erettile nel paziente cardiopatico: diagnosi e raccomandazioni terapeutiche. 124
Positive Predictive Value of Prostate Imaging Reporting and Data System Version 2 for the Detection of Clinically Significant Prostate Cancer: A Systematic Review and Meta-analysis 123
Does previous prostate surgery affect multiparametric magnetic resonance imaging accuracy in detecting clinically significant prostate cancer? Results from a single institution series 120
Prostate-specific membrane antigen Radioguided Surgery to Detect Nodal Metastases in Primary Prostate Cancer Patients Undergoing Robot-assisted Radical Prostatectomy and Extended Pelvic Lymph Node Dissection: Results of a Planned Interim Analysis of a Prospective Phase 2 Study 119
A MINIMUM OF 14 CORES SHOULD BE TAKEN AT BIOPSY BEFORE PLANNING ACTIVE SURVEILLANCE FOR PATIENTS WITH LOW-RISK PROSTATE CANCER 118
Time for action: actinium-225 PSMA-targeted alpha therapy for metastatic prostate cancer – a systematic review and meta-analysis 115
Impact of prostate MRI central review over the diagnostic performance of MRI-targeted biopsy: should we routinely ask for an expert second opinion? 114
Does the administration of preoperative pembrolizumab lead to sustained remission post-cystectomy? First survival outcomes from the PURE-01 study☆ 114
A population-based competing-risks analysis of survival after nephrectomy for renal cell carcinoma 114
Optimizing prostate-targeted biopsy schemes in men with multiple mpMRI visible lesions: should we target all suspicious areas? Results of a two institution series 113
Defining the optimal target-to-background ratio to identify positive lymph nodes in prostate cancer patients undergoing robot-assisted [99mTc]Tc-PSMA radioguided surgery: updated results and ad interim analyses of a prospective phase II study 113
Variability of mpMRI diagnostic performance according to the upfront individual patient risk of having clinically significant prostate cancer 112
Preoperative Erectile Function Represents a Significant Predictor of Postoperative Urinary Continence Recovery in Patients Treated With Bilateral Nerve Sparing Radical Prostatectomy 112
Which Patients with Prostate Cancer and Lymph Node Uptake at Preoperative Prostate-specific Membrane Antigen Positron Emission Tomography/Computerized Tomography Scan Are at a Higher Risk of Prostate-specific Antigen Persistence After Radical Prostatectomy? Identifying Indicators of Systemic Disease by Integrating Clinical, Magnetic Resonance Imaging, and Functional Imaging Parameters 110
Re: Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-Invasive Bladder Carcinoma with Variant Histologies 109
Multiparametric magnetic resonance imaging of the prostate underestimates tumour volume of small visible lesions 106
Long-term Outcomes of Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Not as Good as Previously Thought 104
ASSOCIATION BETWEEN BRCA 1/2 POLYMORPHISMS AND DISEASE AGGRESSIVENESS IN A PROSPECTIVE COHORT OF PROSTATE CANCER PATIENTS UNDERGOING RADICAL PROSTATECTOMY 104
Adjuvant chemotherapy is ineffective in patients with bladder cancer and variant histology treated with radical cystectomy with curative intent 103
Incidence and Clinical Impact of Inflammatory Fluorodeoxyglucose Positron Emission Tomography Uptake After Neoadjuvant Pembrolizumab in Patients with Organ-confined Bladder Cancer Undergoing Radical Cystectomy 103
A Head-to-head Comparison of Four Prognostic Models for Prediction of Lymph Node Invasion in African American and Caucasian Individuals 102
DNA methylation alterations in prostate cancer: from diagnosis to treatment 100
Defining Clinically Meaningful Positive Surgical Margins in Patients Undergoing Radical Prostatectomy for Localised Prostate Cancer 100
ASSOCIATION BETWEEN POLYMORPHISMS OF HOMOLOGOUS RECOMBINATION RAD51B AND DISEASE RECURRENCE IN A PROSPECTIVE COHORT OF PROSTATE CANCER PATIENTS UNDERGOING RADICAL PROSTATECTOMY 99
Assessing the need for systematic biopsies in addition to targeted biopsies according to the characteristics of the index lesion at mpMRI. Results from a large, multi-institutional database 99
A nomogram predicting the cancer-specific mortality in patients eligible for radical cystectomy evaluating clinical data and neoadjuvant cisplatinum-based chemotherapy 99
A Novel Classification Proposal for Rectourethral Fistulas After Primary Treatment of Prostate Cancer 98
External Validation of Nomograms for the Identification of Pelvic Nodal Dissection Candidates Among Prostate Cancer Patients with Negative Preoperative Prostate-specific Membrane Antigen Positron Emission Tomography 97
Diagnostic and prognostic factors in patients with prostate cancer: A systematic review protocol 97
Defining the Most Informative Intermediate Clinical Endpoints for Patients Treated with Salvage Radiotherapy for Prostate-specific Antigen Rise After Radical Prostatectomy 96
Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies 96
ASSOCIATION BETWEEN RS6152 POLYMORPHISM IN THE ANDROGEN RECEPTOR GENE AND DISEASE AGGRESSIVENESS IN A PROSPECTIVE COHORT OF PROSTATE CANCER PATIENTS UNDERGOING RADICAL PROSTATECTOMY 94
Association Between Prostate Imaging Reporting and Data System (PI-RADS) Score for the Index Lesion and Multifocal, Clinically Significant Prostate Cancer 94
Predictive value of preoperative neutrophil-to-lymphocyte ratio in localized prostate cancer: results from a surgical series at a high-volume institution 94
A real-world comparison of docetaxel versus abiraterone acetate for metastatic hormone-sensitive prostate cancer 94
Development and Validation of a Clinical Prognostic Stage Group System for Nonmetastatic Prostate Cancer Using Disease-Specific Mortality Results from the International Staging Collaboration for Cancer of the Prostate 93
Combined Use of Prostate-specific Antigen Density and Magnetic Resonance Imaging for Prostate Biopsy Decision Planning: A Retrospective Multi-institutional Study Using the Prostate Magnetic Resonance Imaging Outcome Database (PROMOD) 93
Association of neurovascular bundle preservation with oncological outcomes in patients with high-risk prostate cancer 92
Reducing the Risk of Postoperative Complications After Robot-assisted Radical Prostatectomy in Prostate Cancer Patients: Results of an Audit and Feedback Intervention Following the Implementation of Prospective Data Collection 92
There Is No Way to Avoid Systematic Prostate Biopsies in Addition to Multiparametric Magnetic Resonance Imaging Targeted Biopsies 91
Definition and Impact on Oncologic Outcomes of Persistently Elevated Prostate-specific Antigen After Salvage Lymph Node Dissection for Node-only Recurrent Prostate Cancer After Radical Prostatectomy: Clinical Implications for Multimodal Therapy 91
Assessing the Clinical Value of Positive Multiparametric Magnetic Resonance Imaging in Young Men with a Suspicion of Prostate Cancer 90
Predictors of 30-day acute kidney injury following radical and partial nephrectomy for renal cell carcinoma 90
Prognostic Implications of Multiparametric Magnetic Resonance Imaging and Concomitant Systematic Biopsy in Predicting Biochemical Recurrence After Radical Prostatectomy in Prostate Cancer Patients Diagnosed with Magnetic Resonance Imaging-targeted Biopsy 89
Radioguided Surgery for Prostate Cancer 88
Introducing PIONEER: a project to harness big data in prostate cancer research 88
A Systematic Review of Focal Ablative Therapy for Clinically Localised Prostate Cancer in Comparison with Standard Management Options: Limitations of the Available Evidence and Recommendations for Clinical Practice and Further Research 88
Assessing the Best Surgical Template at Salvage Pelvic Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: When Can Bilateral Dissection be Omitted? Results from a Multi-institutional Series 88
Assessing the Impact of Surgeon Experience on Urinary Continence Recovery after Robot-Assisted Radical Prostatectomy: Results of Four High-Volume Surgeons 87
A NOVEL TOOL FOR THE PREDICTION OF URINARY INCONTINENCE AFTER BILATERAL NERVE SPARING RADICAL PROSTATECTOMY 85
A SINGLE POSITIVE LYMPH NODE HAS NO DETRIMENTAL EFFECT ON SURVIVAL OF PATIENTS WITH PROSTATE CANCER TREATED WITH EXTENDED PELVIC LYMPH NODE DISSECTION. RESULTS OF A MATCHED CONTROLLED ANALYSIS 85
A detailed analysis of the association between postoperative phosphodiesterase type 5 inhibitor use and the risk of biochemical recurrence after radical prostatectomy 84
A novel tool for the prediction of urinary incontinence after bilateral nerve-sparing radical prostatectomy 83
Can Patients with Muscle-invasive Bladder Cancer and Fibroblast Growth Factor Receptor-3 Alterations Still Be Considered for Neoadjuvant Pembrolizumab? A Comprehensive Assessment from the Updated Results of the PURE-01 Study 83
A single positive lymph node has no detrimental effect on survival of patients with prostate cancer treated with extended pelvic lymph node dissection. Results of a matched controlled analysis 82
Conversion of Robot-assisted Partial Nephrectomy to Radical Nephrectomy: A Prospective Multi-institutional Study 81
Surgical Safety of Radical Cystectomy and Pelvic Lymph Node Dissection Following Neoadjuvant Pembrolizumab in Patients with Bladder Cancer: Prospective Assessment of Perioperative Outcomes from the PURE-01 Trial 81
EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer—2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent 81
"Trifecta' outcomes of robot-assisted partial nephrectomy in solitary kidney: a Vattikuti Collective Quality Initiative (VCQI) database analysis 80
Prostate-specific Membrane Antigen Imaging in Clinical Guidelines: European Association of Urology, National Comprehensive Cancer Network, and Beyond 80
Prediction of the Need for an Extended Lymphadenectomy at the Time of Radical Cystectomy in Patients with Bladder Cancer 79
Author Correction: Introducing PIONEER: a project to harness big data in prostate cancer research (Nature Reviews Urology, (2020), 17, 6, (351-362), 10.1038/s41585-020-0324-x) 79
Reply by Authors 79
Technical and Functional Validation of a Teleoperated Multirobots Platform for Minimally Invasive Surgery 78
Distribution of metastatic sites in patients with prostate cancer: A population-based analysis 78
Long-term Cancer Control Outcomes in Patients with Clinically High-risk Prostate Cancer Treated with Robot-assisted Radical Prostatectomy: Results from a Multi-institutional Study of 1100 Patients 78
Long-term utility of adjuvant hormonal and radiation therapy for patients with seminal vesicle invasion at radical prostatectomy 78
A SINGLE POSITIVE LYMPH NODE HAS NO DETRIMENTAL EFFECT ON SURVIVAL OF PATIENTS WITH PROSTATE CANCER TREATED WITH EXTENDED PELVIC LYMPH NODE DISSECTION. RESULTS OF A MATCHED CONTROLLED ANALYSIS 78
Risk Stratification of Patients Candidate to Radical Prostatectomy Based on Clinical and Multiparametric Magnetic Resonance Imaging Parameters: Development and External Validation of Novel Risk Groups 78
Safety and Early Oncologic Outcomes of Lung Resection in Patients with Isolated Pulmonary Recurrent Prostate Cancer: A Single-center Experience 77
Controversies in MR targeted biopsy: alone or combined, cognitive versus software-based fusion, transrectal versus transperineal approach? 77
Association between Lesion Location and Oncologic Outcomes after Focal Therapy for Localized Prostate Cancer Using Either High Intensity Focused Ultrasound or Cryotherapy 77
Improving the stratification of intermediate risk prostate cancer 77
EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II—2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer 75
Does HistoScanning (TM) predict positive results in prostate biopsy? A retrospective analysis of 1,188 sextants of the prostate 74
Early Catheter Removal after Robot-assisted Radical Prostatectomy: Surgical Technique and Outcomes for the Aalst Technique (ECaRemA Study) 72
A Systematic Review of the Emerging Role of Immune Checkpoint Inhibitors in Metastatic Castration-resistant Prostate Cancer: Will Combination Strategies Improve Efficacy? 72
Followup of Men with PI-RADS™ 4 or 5 Abnormality on Prostate Magnetic Resonance Imaging and Nonmalignant Pathological Findings on Initial Targeted Prostate Biopsy. Letter 72
Assessing the Role and Optimal Duration of Hormonal Treatment in Association with Salvage Radiation Therapy After Radical Prostatectomy: Results from a Multi-Institutional Study 71
A Systematic Review of the Impact of Surgeon and Hospital Caseload Volume on Oncological and Nononcological Outcomes After Radical Prostatectomy for Nonmetastatic Prostate Cancer 71
Delay in Nephrectomy and Cancer Control Outcomes in Elderly Patients with Small Renal Masses 70
The added value of artificial intelligence using Quantib Prostate for the detection of prostate cancer at multiparametric magnetic resonance imaging 69
A systematic review of the association between erectile dysfunction and cardiovascular disease 69
Upper Tract Urothelial Carcinoma in the Lynch Syndrome Tumour Spectrum: A Comprehensive Overview from the European Association of Urology - Young Academic Urologists and the Global Society of Rare Genitourinary Tumors 69
Totale 11.749
Salva come PNG Salva come JPEG
Categoria #
all - tutte 179.228
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 179.228
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022364 0 48 39 116 13 19 31 24 10 14 21 29
2022/20232.140 964 443 116 26 15 230 91 136 59 8 28 24
2023/20241.237 24 48 106 92 89 214 116 126 16 110 122 174
2024/20256.038 829 157 149 140 174 496 722 500 1.105 887 407 472
2025/202617.565 1.213 1.445 1.359 2.567 1.190 399 1.476 1.188 4.589 1.002 700 437
Totale 27.630